Listed

Inmune Bio, Inc.

INMBNasdaqCIK 1711754HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2025
Operating income−$1.5m, Q2 FY2026
Net income−$1.3m, Q2 FY2026
Inmune Bio, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.0Revenue, Q3 FY2023, three months to 2023-09-30$43.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$28.0k. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-27, accession 0001013762-25-003354. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2024, three months to 2024-03-31$14.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figure0.0Revenue, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-08-07, accession 0001213900-25-073077. Derived: 6-month figure less the 3-month figure.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-10-30, accession 0001213900-25-104141. Derived: 9-month figure less the 6-month figure.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-30, accession 0001213900-26-036370. Derived: 12-month figure less the 9-month figure.Report this figure0.1Revenue, Q1 FY2025, three months to 2025-03-31$50.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001213900-26-086135. Derived: 6-month figure less the 3-month figure.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-10-30, accession 0001213900-25-104141. Derived: 9-month figure less the 6-month figure.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-30, accession 0001213900-26-036370. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Research and development$m6.0Research and development, Q3 FY2023, three months to 2023-09-30$6.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figure6.0Research and development, Q4 FY2023, three months to 2023-12-31$6.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-27, accession 0001013762-25-003354. Derived: 12-month figure less the 9-month figure.Report this figure8.7Research and development, Q1 FY2024, three months to 2024-03-31$8.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figure7.1Research and development, Q2 FY2024, three months to 2024-06-30$7.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001213900-25-073077.Report this figure10.1Research and development, Q3 FY2024, three months to 2024-09-30$10.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure7.4Research and development, Q4 FY2024, three months to 2024-12-31$7.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001213900-26-036370. Derived: 12-month figure less the 9-month figure.Report this figure7.6Research and development, Q1 FY2025, three months to 2025-03-31$7.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure5.8Research and development, Q2 FY2025, three months to 2025-06-30$5.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001213900-25-073077.Report this figure4.9Research and development, Q3 FY2025, three months to 2025-09-30$4.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure2.3Research and development, Q4 FY2025, three months to 2025-12-31$2.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001213900-26-036370. Derived: 12-month figure less the 9-month figure.Report this figure3.6Research and development, Q1 FY2026, three months to 2026-03-31$3.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figurenot reported
Operating income$m(8.5)Operating income, Q3 FY2023, three months to 2023-09-30−$8.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figure(8.4)Operating income, Q4 FY2023, three months to 2023-12-31−$8.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-27, accession 0001013762-25-003354. Derived: 12-month figure less the 9-month figure.Report this figure(11.0)Operating income, Q1 FY2024, three months to 2024-03-31−$11.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figure(9.9)Operating income, Q2 FY2024, three months to 2024-06-30−$9.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001213900-25-073077.Report this figure(12.3)Operating income, Q3 FY2024, three months to 2024-09-30−$12.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure(9.5)Operating income, Q4 FY2024, three months to 2024-12-31−$9.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001213900-26-036370. Derived: 12-month figure less the 9-month figure.Report this figure(9.9)Operating income, Q1 FY2025, three months to 2025-03-31−$9.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure(24.6)Operating income, Q2 FY2025, three months to 2025-06-30−$24.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure(7.4)Operating income, Q3 FY2025, three months to 2025-09-30−$7.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure(5.5)Operating income, Q4 FY2025, three months to 2025-12-31−$5.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001213900-26-036370. Derived: 12-month figure less the 9-month figure.Report this figure(5.8)Operating income, Q1 FY2026, three months to 2026-03-31−$5.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure(1.5)Operating income, Q2 FY2026, three months to 2026-06-30−$1.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure
Interest expense$m0.6Interest expense, Q3 FY2023, three months to 2023-09-30$568.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figure0.5Interest expense, Q4 FY2023, three months to 2023-12-31$467.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2025-03-27, accession 0001013762-25-003354. Derived: 12-month figure less the 9-month figure.Report this figure0.4Interest expense, Q1 FY2024, three months to 2024-03-31$357.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-09, accession 0001213900-24-041286.Report this figure0.3Interest expense, Q2 FY2024, three months to 2024-06-30$250.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-08-01, accession 0001213900-24-064076.Report this figure0.1Interest expense, Q3 FY2024, three months to 2024-09-30$145.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figure(0.4)Interest expense, Q4 FY2024, three months to 2024-12-31−$395.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-05-08, accession 0001213900-25-041072. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figurenot reportednot reportednot reportednot reportednot reported
Net income$m(8.6)Net income, Q3 FY2023, three months to 2023-09-30−$8.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figure(8.4)Net income, Q4 FY2023, three months to 2023-12-31−$8.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-27, accession 0001013762-25-003354. Derived: 12-month figure less the 9-month figure.Report this figure(11.0)Net income, Q1 FY2024, three months to 2024-03-31−$11.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure(9.7)Net income, Q2 FY2024, three months to 2024-06-30−$9.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure(12.1)Net income, Q3 FY2024, three months to 2024-09-30−$12.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure(9.2)Net income, Q4 FY2024, three months to 2024-12-31−$9.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001213900-26-036370. Derived: 12-month figure less the 9-month figure.Report this figure(9.7)Net income, Q1 FY2025, three months to 2025-03-31−$9.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure(24.5)Net income, Q2 FY2025, three months to 2025-06-30−$24.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure(6.5)Net income, Q3 FY2025, three months to 2025-09-30−$6.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure(5.3)Net income, Q4 FY2025, three months to 2025-12-31−$5.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001213900-26-036370. Derived: 12-month figure less the 9-month figure.Report this figure(5.4)Net income, Q1 FY2026, three months to 2026-03-31−$5.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure(1.3)Net income, Q2 FY2026, three months to 2026-06-30−$1.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure
Diluted EPS$ per share(0.48)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figurenot reported(0.61)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.61 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figure(0.50)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001213900-25-073077.Report this figure(0.60)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.60 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figurenot reported(0.43)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure(1.05)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$1.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure(0.24)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figurenot reported(0.20)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure(0.05)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure
Basic EPS$ per share(0.48)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.48 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figurenot reported(0.61)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.61 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figure(0.50)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001213900-25-073077.Report this figure(0.60)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.60 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figurenot reported(0.43)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.43 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure(1.05)Basic EPS, Q2 FY2025, three months to 2025-06-30−$1.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure(0.24)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figurenot reported(0.20)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure(0.05)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure

Balance sheet

Cash and equivalents$24.8m, FY2025
Long-term debt$15.0m, Q2 FY2025
Shareholders' equity$20.4m, Q2 FY2026
Inmune Bio, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m41.8Cash and equivalents, Q3 FY2023, at 2023-09-30$41.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-01, accession 0001213900-23-082167.Report this figure35.8Cash and equivalents, FY2023, at 2023-12-31$35.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-27, accession 0001013762-25-003354.Report this figure26.0Cash and equivalents, Q1 FY2024, at 2024-03-31$26.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0001213900-24-041286.Report this figure31.1Cash and equivalents, Q2 FY2024, at 2024-06-30$31.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-01, accession 0001213900-24-064076.Report this figure33.6Cash and equivalents, Q3 FY2024, at 2024-09-30$33.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figure20.9Cash and equivalents, FY2024, at 2024-12-31$20.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-30, accession 0001213900-26-036370.Report this figure19.3Cash and equivalents, Q1 FY2025, at 2025-03-31$19.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figure33.4Cash and equivalents, Q2 FY2025, at 2025-06-30$33.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001213900-25-073077.Report this figure27.7Cash and equivalents, Q3 FY2025, at 2025-09-30$27.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure24.8Cash and equivalents, FY2025, at 2025-12-31$24.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-30, accession 0001213900-26-036370.Report this figurenot reportednot reported
Current assets$m45.6Current assets, Q3 FY2023, at 2023-09-30$45.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-01, accession 0001213900-23-082167.Report this figure39.9Current assets, FY2023, at 2023-12-31$39.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-27, accession 0001013762-25-003354.Report this figure29.8Current assets, Q1 FY2024, at 2024-03-31$29.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001213900-24-041286.Report this figure35.5Current assets, Q2 FY2024, at 2024-06-30$35.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-01, accession 0001213900-24-064076.Report this figure35.9Current assets, Q3 FY2024, at 2024-09-30$35.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figure22.7Current assets, FY2024, at 2024-12-31$22.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-30, accession 0001213900-26-036370.Report this figure21.0Current assets, Q1 FY2025, at 2025-03-31$21.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figure36.0Current assets, Q2 FY2025, at 2025-06-30$36.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001213900-25-073077.Report this figure30.7Current assets, Q3 FY2025, at 2025-09-30$30.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure29.9Current assets, FY2025, at 2025-12-31$29.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure22.8Current assets, Q1 FY2026, at 2026-03-31$22.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure23.8Current assets, Q2 FY2026, at 2026-06-30$23.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure
Total assets$m62.7Total assets, Q3 FY2023, at 2023-09-30$62.7m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-01, accession 0001213900-23-082167.Report this figure57.0Total assets, FY2023, at 2023-12-31$57.0m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-27, accession 0001013762-25-003354.Report this figure46.8Total assets, Q1 FY2024, at 2024-03-31$46.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001213900-24-041286.Report this figure52.5Total assets, Q2 FY2024, at 2024-06-30$52.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-01, accession 0001213900-24-064076.Report this figure52.8Total assets, Q3 FY2024, at 2024-09-30$52.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figure39.6Total assets, FY2024, at 2024-12-31$39.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-30, accession 0001213900-26-036370.Report this figure37.8Total assets, Q1 FY2025, at 2025-03-31$37.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figure37.7Total assets, Q2 FY2025, at 2025-06-30$37.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001213900-25-073077.Report this figure33.4Total assets, Q3 FY2025, at 2025-09-30$33.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure32.4Total assets, FY2025, at 2025-12-31$32.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure25.8Total assets, Q1 FY2026, at 2026-03-31$25.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure26.8Total assets, Q2 FY2026, at 2026-06-30$26.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure
Current liabilities$m14.4Current liabilities, Q3 FY2023, at 2023-09-30$14.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-01, accession 0001213900-23-082167.Report this figure18.5Current liabilities, FY2023, at 2023-12-31$18.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-27, accession 0001013762-25-003354.Report this figure17.5Current liabilities, Q1 FY2024, at 2024-03-31$17.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001213900-24-041286.Report this figure15.1Current liabilities, Q2 FY2024, at 2024-06-30$15.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-01, accession 0001213900-24-064076.Report this figure13.8Current liabilities, Q3 FY2024, at 2024-09-30$13.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figure7.2Current liabilities, FY2024, at 2024-12-31$7.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-30, accession 0001213900-26-036370.Report this figure7.9Current liabilities, Q1 FY2025, at 2025-03-31$7.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figure8.6Current liabilities, Q2 FY2025, at 2025-06-30$8.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001213900-25-073077.Report this figure7.4Current liabilities, Q3 FY2025, at 2025-09-30$7.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure8.4Current liabilities, FY2025, at 2025-12-31$8.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure5.4Current liabilities, Q1 FY2026, at 2026-03-31$5.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure5.9Current liabilities, Q2 FY2026, at 2026-06-30$5.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure
Total liabilities$m18.0Total liabilities, Q3 FY2023, at 2023-09-30$18.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-01, accession 0001213900-23-082167.Report this figure18.9Total liabilities, FY2023, at 2023-12-31$18.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-27, accession 0001013762-25-003354.Report this figure17.8Total liabilities, Q1 FY2024, at 2024-03-31$17.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0001213900-24-041286.Report this figure15.4Total liabilities, Q2 FY2024, at 2024-06-30$15.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-01, accession 0001213900-24-064076.Report this figure14.1Total liabilities, Q3 FY2024, at 2024-09-30$14.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figure7.5Total liabilities, FY2024, at 2024-12-31$7.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-30, accession 0001213900-26-036370.Report this figure8.1Total liabilities, Q1 FY2025, at 2025-03-31$8.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figure8.8Total liabilities, Q2 FY2025, at 2025-06-30$8.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001213900-25-073077.Report this figure8.0Total liabilities, Q3 FY2025, at 2025-09-30$8.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure8.8Total liabilities, FY2025, at 2025-12-31$8.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure6.2Total liabilities, Q1 FY2026, at 2026-03-31$6.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure6.5Total liabilities, Q2 FY2026, at 2026-06-30$6.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure
Long-term debt$m12.5Long-term debt, Q3 FY2023, at 2023-09-30$12.5m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2023-11-01, accession 0001213900-23-082167.Report this figurenot reportednot reportednot reportednot reported15.0Long-term debt, FY2024, at 2024-12-31$15.0m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2025-03-27, accession 0001013762-25-003354.Report this figure15.0Long-term debt, Q1 FY2025, at 2025-03-31$15.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figure15.0Long-term debt, Q2 FY2025, at 2025-06-30$15.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-08-07, accession 0001213900-25-073077.Report this figurenot reportednot reportednot reportednot reported
Current portion of debt$mnot reported9.9Current portion of debt, FY2023, at 2023-12-31$9.9m. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2025-03-27, accession 0001013762-25-003354.Report this figure7.5Current portion of debt, Q1 FY2024, at 2024-03-31$7.5m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2024-05-09, accession 0001213900-24-041286.Report this figure5.0Current portion of debt, Q2 FY2024, at 2024-06-30$5.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2024-08-01, accession 0001213900-24-064076.Report this figure2.5Current portion of debt, Q3 FY2024, at 2024-09-30$2.5m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m43.9Shareholders' equity, Q3 FY2023, at 2023-09-30$43.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figure37.3Shareholders' equity, FY2023, at 2023-12-31$37.3m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-30, accession 0001213900-26-036370.Report this figure28.2Shareholders' equity, Q1 FY2024, at 2024-03-31$28.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure36.3Shareholders' equity, Q2 FY2024, at 2024-06-30$36.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure38.7Shareholders' equity, Q3 FY2024, at 2024-09-30$38.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure32.1Shareholders' equity, FY2024, at 2024-12-31$32.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure29.7Shareholders' equity, Q1 FY2025, at 2025-03-31$29.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure28.9Shareholders' equity, Q2 FY2025, at 2025-06-30$28.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure25.4Shareholders' equity, Q3 FY2025, at 2025-09-30$25.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure23.5Shareholders' equity, FY2025, at 2025-12-31$23.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure19.6Shareholders' equity, Q1 FY2026, at 2026-03-31$19.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure20.4Shareholders' equity, Q2 FY2026, at 2026-06-30$20.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure

Cash flow

Operating cash flow−$3.2m, Q2 FY2026
Capital expenditure$143.0k, Q4 FY2025
Inmune Bio, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(4.3)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$4.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-10-31, accession 0001213900-24-092861. Derived: 9-month figure less the 6-month figure.Report this figure(3.4)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-27, accession 0001013762-25-003354. Derived: 12-month figure less the 9-month figure.Report this figure(7.5)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$7.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figure(7.9)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$7.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001213900-25-073077. Derived: 6-month figure less the 3-month figure.Report this figure(7.0)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$7.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0001213900-25-104141. Derived: 9-month figure less the 6-month figure.Report this figure(11.0)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$11.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001213900-26-036370. Derived: 12-month figure less the 9-month figure.Report this figure(6.8)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$6.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure(7.4)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$7.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001213900-26-086135. Derived: 6-month figure less the 3-month figure.Report this figure(5.4)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$5.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0001213900-25-104141. Derived: 9-month figure less the 6-month figure.Report this figure(2.9)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001213900-26-036370. Derived: 12-month figure less the 9-month figure.Report this figure(3.4)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure(3.2)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001213900-26-086135. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported0.2Capital expenditure, Q3 FY2025, three months to 2025-09-30$193.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-30, accession 0001213900-25-104141. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$143.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001213900-26-036370. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)26.72m, Q2 FY2026
Inmune Bio, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares17.9Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3017,945,995 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-01, accession 0001213900-23-082167.Report this figure17.9Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3117,945,995 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0001213900-24-041286.Report this figure17.9Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3017,945,995 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-01, accession 0001213900-24-064076.Report this figure18.0Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3018,008,295 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-10-31, accession 0001213900-24-092861.Report this figure18.0Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3118,026,473 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001213900-25-041072.Report this figure19.3Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3019,307,323 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001213900-25-073077.Report this figure20.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3020,185,676 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure22.5Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3122,496,191 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure23.3Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3023,298,455 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure26.6Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3026,585,258 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-10-30, accession 0001213900-25-104141.Report this figure26.6Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3126,585,258 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001213900-26-053338.Report this figure26.7Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3026,718,507 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure

Shares outstanding: 27.75mShares outstanding, period not labelled, at 2026-08-0627,753,789 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001213900-26-086135.Report this figure at Aug 6, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.